FMP
Trevi Therapeutics, Inc.
TRVI
NASDAQ
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
4.05 USD
-0.1 (-2.47%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Ms. Jennifer L. Good
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
CIK
0001563880
ISIN
US89532M1018
CUSIP
89532M101
Address
195 Church Street
Phone
203 304 2499
Country
US
Employee
27
IPO Date
May 7, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
TRVI Financial Summary
CIK
0001563880
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
89532M101
ISIN
US89532M1018
Country
US
Price
4.05
Beta
1.01
Volume Avg.
1.67M
Market Cap
361.93M
Shares
-
52-Week
1.27-4.675
DCF
0.31
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-9.2
P/B
-
Website
https://www.trevitherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TRVI News
It looks like there's no news available.
